"The trial will enrol male patients with metastatic castrate-resistant prostate cancer who have responded to prior lutetium 177 (¹⁷⁷Lu)-PSMA therapy."
clinicaltrialsarena.com/new...
it's phase 1/2 but actinium is very interesting especially against micro metastasis